ReviewFrontiers in oncology2025
Advances in targeting protein S-palmitoylation in tumor immunity and therapy.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Genetically predicted ZDHHC8 expression and osteoporosis risk: A two-sample Mendelian randomization and metabolite mediation study.Medicine · 2026Article
- ProteinJournal of pharmaceutical analysis · 2026Review
- Palmitoylation-dependent regulation of innate and adaptive immunity: molecular insights and translational opportunities.Cellular & molecular biology letters · 2026Review
- ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression.Cell death & disease · 2026Article
- ZDHHC-Mediated Protein S-Palmitoylation in Cancer: Epigenetic Interfaces, Structural Logic and Therapeutic Targeting.International journal of medical sciences · 2026Review
- The emerging role of ZDHHC9 in cancer: from protein palmitoylation to tumor progression and immune regulation.Frontiers in immunology · 2026Review
- Protein palmitoylation in hematological malignancies: mechanistic links to lipid metabolic reprogramming and therapy resistance.Frontiers in immunology · 2026Review
- Bridging metabolic reprogramming and targeted therapy: the critical role of S-palmitoylation in cancer.Frontiers in cell and developmental biology · 2026Review
- The Roles of ProteinCancer communications (London, England) · 2026Review
- Zinc-mediated dynamics of CD4/CD8α co-receptors and Lck kinase: implications for zinc homeostasis, immune response, and biotechnological innovations.Metallomics : integrated biometal science · 2025Review
- Systematic analysis of ZDHHC9 as a potential prognostic and immunotherapy biomarker in breast cancer.Frontiers in immunology · 2025Article
- Integrated Genomic and Functional Characterization of Palmitoylation in Clear Cell Renal Cell Carcinoma.Human mutation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
S-palmitoylation is a reversible and dynamic post-translational modification of proteins. A palmitoyl group is covalently attached to a cysteine residue of the protein by a thioester link. It regulates the transcription and expression of downstream target genes and cell signaling, influencing cellular functions. Research indicates a substantial correlation between S-palmitoylation and tumorigenesis and immunotherapy, where it plays a pivotal role in modulating T cell activation, cytokine signaling, autophagy, phagocytosis, and death. Moreover, palmitoylation contributes to drug resistance and immunological evasion in tumor cells, enabling them to circumvent the effects of chemotherapeutic drugs and immune surveillance. Inhibitors that target S-palmitoylation have demonstrated significant potential in enhancing the efficacy of tumor immunotherapy, offering a novel strategy for cancer treatment. Nonetheless, obstacles such as inhibitor specificity and efficacy persist, requiring more extensive investigations into the exact mechanisms of S-palmitoylation to develop more effective targeted therapeutics. This article summarizes recent developments in S-palmitoylation concerning tumor immunity and treatment. The article examines the regulatory function of S-palmitoylation, its modifying enzymes in tumor cell signaling, and novel tumor immunotherapies that target S-palmitoylation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.